Serum nm23-H1 protein as a prognostic factor for indolent non-Hodgkin's lymphoma
Open Access
- 1 May 2001
- journal article
- research article
- Published by Springer Science and Business Media LLC in Leukemia
- Vol. 15 (5), 832-839
- https://doi.org/10.1038/sj.leu.2402105
Abstract
Standard chemotherapy has been ineffective for improving the poor 10-year survival rate of patients with indolent lymphoma. However, a wider choice of therapeutic modalities has become recently available, including immunotherapy with monoclonal antibodies and allogeneic peripheral blood stem cell transplantation. Accordingly, a sensitive prognostic indicator is required to identify high-risk patients and to help design new therapeutic approaches for them. We previously reported that the serum nm23-H1 protein level was an independent prognostic factor for aggressive lymphoma. The present study was performed to assess the clinical implications of this protein on indolent lymphoma and whether it can be used to classify the aggressiveness of the disease in order to assist in the individualization of therapy. A total of 130 patients with indolent lymphoma were enrolled in this multicenter study. The serum nm23-H1 protein level was significantly higher in patients with indolent lymphoma than in a normal control group. In addition, indolent lymphoma patients with higher nm23-H1 levels had worse overall and progression-free survival rate than those with lower nm23-H1 levels. Therefore, nm23-H1 in serum may be useful for identifying a distinct group of patients at high risk.This publication has 25 references indexed in Scilit:
- nm23: Unraveling its biological function in cell differentiationJournal of Cellular Physiology, 2000
- A new function of Nm23/NDP kinase as a differentiation inhibitory factor, which does not require it's kinase activityFEBS Letters, 1995
- A Predictive Model for Aggressive Non-Hodgkin's LymphomaThe New England Journal of Medicine, 1993
- Identification of Prognostic Groups in Follicular LymphomaLeukemia & Lymphoma, 1993
- Identity of a differentiation inhibiting factor for mouse myeloid leukemia cells with NM23/nucleoside diphosphate kinaseBiochemical and Biophysical Research Communications, 1992
- Prognostic indicators in centroblastic-centrocytic lymphoma.Journal of Clinical Pathology, 1988
- Evidence for a Novel Gene Associated With Low Tumor Metastatic PotentialJNCI Journal of the National Cancer Institute, 1988
- The Natural History of Initially Untreated Low-Grade Non-Hodgkin's LymphomasThe New England Journal of Medicine, 1984
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958
- Individual Comparisons by Ranking MethodsBiometrics Bulletin, 1945